HIV Vaccine

Preclinical Results Are Promising

Published in Vaccine Weekly, December 26th, 2001

CEL-SCI Corporation announced researchers have demonstrated that animals given CEL-SCI's experimental L.E.A.P.S.-based HIV vaccine agent showed strong evidence supporting the induction of cellular immune responses and antibodies, both of which recognize different strains of the HIV virus.

Potentially even more important to the field of vaccine research is the finding that, even after repeat administration, only minimal immune responses were developed against the delivery peptides used by the L.E.A.P.S. technology (called a T-cell binding ligand), while strong immune responses were elicited against the HIV portion of the peptide. This may indicate that, unlike other...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-12-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry